---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-010239"
form_type: "8-K"
ticker: "PTN"
cik: "0000911216"
company_name: "PALATIN TECHNOLOGIES INC"
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T03:29:43.121735+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Palatin: Fosun reports first Vyleesi sale in China; Kwangdong completes Phase 3 enrollment

## Summary
- Fosun dispensed first Vyleesi prescription in Hainan Province, China.
- Kwangdong completed Phase 3 enrollment: 193 patients enrolled, 180 completed (93%).
- Data from Korea trial expected by year end; potential MFDS submission in H1 2024.
- Palatin eligible for up to $92.5M in milestones from Fosun plus royalties; $3M milestone from Kwangdong.
- Vyleesi is only FDA-approved as-needed HSDD treatment; Palatin reported six consecutive quarters of double-digit prescription growth.

## SEC filing metadata
- accession: 0001654954-23-010239
- form_type: 8-K
- ticker: PTN
- cik: 0000911216
- company_name: PALATIN TECHNOLOGIES INC
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/911216/000165495423010239/0001654954-23-010239-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/911216/000165495423010239/ptn_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-010239
- JSON: https://secwatch.observer/filing/0001654954-23-010239.json
- Plain text: https://secwatch.observer/filing/0001654954-23-010239.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.